SutroVax Announces Closing of $64M via Series B Financing

SutroVax Announces Closing of $64M via Series B Financing Foster City, CA, March 21, 2017 – SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious...

American Society of Hematology (ASH) 2016 – Poster

American Society of Hematology (ASH) 2016 – Poster Discovery and preclinical development of novel CD74-targeting antibody-drug conjugates (ADCs) with significant activity in multiple myeloma (MM) cell lines and xenograft models 2016 DEC ASH MM Poster final no...

BioTech Nation Radio with CEO Bill Newell

BioTech Nation Radio with CEO Bill Newell NPR and BioTech Nation interview Sutro’s CEO William Newell to learn more about the next generation of cancer therapeutics. Click here to listen to the conversation as Bill describes Sutro’s discovery and...
Sutro Biopharma, Inc.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.